On 26 January 2026, MS Pharma announced that it has entered an exclusive agreement with Hetero Group in relation to the commercialisation in Algeria of 5 undisclosed “established biosimilars” in therapeutic areas including oncology, immunology and haematology.
The biosimilar portfolio is reported to have an estimated total market value of USD 45 million in Algeria (as of 2024). The agreement will be implemented by MS Pharma’s Algerian affiliate, El Kendi, and Hetero Group’s subsidiary, Hetero Biopharma, and will involve “localisation and technology transfer”.
MS Pharma has entered into a number of agreements for commercialisation of biosimilars in the MENA region over the last year, including with Formycon for biosimilar pembrolizumab (December 2025); Polpharma for biosimilar guselkumab, ocrelizumab and vedolizumab (September 2025); and Kashiv Biosciences for biosimilar omalizumab (August 2025).